Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 29+6 Weeks Gestational Age

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Ottawa Hospital Research Institute
Sponsor:
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01709409
First received: October 12, 2012
Last updated: September 27, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to see if a medication called Curosurf can reduce the length of time that small premature babies with Respiratory Distress Syndrome (immature lungs) or RDS, stay on the ventilator, as compared to the standard medication called BLES. Curosurf is a medication that is already used in other countries around the world but not yet in Canada.

Babies born under 30 weeks of gestation frequently need respiratory support after birth, including being placed on a breathing machine or respirator. The most common reason is Respiratory Distress Syndrome (RDS) whereby immature lungs don't produce enough surfactant, a soapy like substance that helps the air sacs open and close. Our current standard treatment is a surfactant called BLES. Curosurf contains more active ingredient per volume therefore the amount is smaller. The investigators hypothesize that babies who receive Curosurf will be able to be removed from the ventilator sooner.

Babies in this study will have a 50/50 chance of receiving either Curosurf or BLES and the investigators will monitor their progress during their Neonatal Intensive Care Unit admission.

The study is taking place in Canada. The goal is to enroll 88 babies. There are no extra tests (blood tests or X-Rays) or return visits to the hospital for the purposes of this study.


Condition Intervention Phase
Respiratory Distress Syndrome
Drug: Curosurf-Group1
Drug: BLES-group 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Partially Double-blinded, Phase 3, Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 29+6 Weeks Gestational Age

Resource links provided by NLM:


Further study details as provided by Ottawa Hospital Research Institute:

Primary Outcome Measures:
  • The primary objective of the study is to compare between the two groups, the number of subjects alive and extubated at 48 hours post surfactant administration. Extubation [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]
    1. rate on ventilator ≤40 per minute and
    2. mean airway pressure ≤ 10 cm H20 and
    3. fi02 ≤ 30%


Secondary Outcome Measures:
  • To compare the duration of respiratory support, extubation failure rates, need for additional surfactant doses, adverse events (during and following administration), survival and pulmonary morbidities during hospital admission between the two groups. [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    1. Extubation failure

  • Curosurf-01 [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    2. Duration of first intubation (in hours/days)

  • Curosurf-01 [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    3. Total duration of respiratory support (ventilator and nCPAP) and total number of days of oxygen requirement

  • Curosurf-01 [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    4. Number of doses of surfactant received

  • Curosurf-01 [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    5. Adverse events during or after administration of surfactant

  • Curosurf-01 [ Time Frame: 36 Weeks GA ] [ Designated as safety issue: Yes ]
    6. Bronchopulmonary dysplasia, defined as oxygen or respiratory support requirement at 36 weeks corrected GA

  • Curosurf-01 [ Time Frame: 36 weeks GA ] [ Designated as safety issue: Yes ]
    7. Mortality prior to discharge


Estimated Enrollment: 88
Study Start Date: March 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Curosurf (Group 1)
Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
Drug: Curosurf-Group1
Maximum of 3 doses are administered to infants diagnosed with RDS.
Active Comparator: BLES (Group 2)
Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
Drug: BLES-group 2
Maximum of 3 doses are administered to infants with RDS

  Eligibility

Ages Eligible for Study:   24 Weeks to 29 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Infants born between 24+0 and 29+6 weeks gestational age, admitted to the study centers
  2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after birth

Exclusion Criteria:

  1. Any infant more than 48 hours of age
  2. Any infant with a pulmonary hemorrhage
  3. Any infant with life-threatening congenital anomaly or one that is considered non-viable
  4. Any infant on a high frequency ventilator
  5. Any infant known to require early intubation and ventilation for surgical treatment of a congenital anomaly
  6. Any infant with anomalies of the upper or lower airway or mandible precluding use of nCPAP
  7. Any infant born after prolonged premature rupture of membranes (<22 weeks GA or >14 days prior to delivery)
  8. A parent/LAR who is incapable of, or unwilling, to give consent
  9. Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol
  10. Any other reason as deemed significant by the Investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01709409

Contacts
Contact: Brigitte Lemyre, MD 6137378899 ext 71882 blemyre@ottawahospital.on.ca
Contact: Lynne Cullen, RN 6137377600 ext 3782 lcullen@cheo.on.ca

Locations
Canada, Ontario
The Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H8L6
Contact: Lynne Cullen, RN    6137377600 ext 3782    lcullen@cheo.on.ca   
Contact: Samantha Somers, BA    6137377600 ext 2794    ssomers@cheo.on.ca   
Principal Investigator: Brigitte Lemyre, MD         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Investigators
Principal Investigator: Brigitte Lemyre, MD OHRI
  More Information

Additional Information:
No publications provided

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT01709409     History of Changes
Other Study ID Numbers: Curosurf-01
Study First Received: October 12, 2012
Last Updated: September 27, 2013
Health Authority: Canada: Health Canada
Canada: Ethics Review Committee

Keywords provided by Ottawa Hospital Research Institute:
Prematurity

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Newborn
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Diseases
Respiration Disorders
Respiratory Tract Diseases
Poractant alfa
Pharmacologic Actions
Pulmonary Surfactants
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014